Low- versus Standard-Dose Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke: An Updated Meta-Analysis

医学 改良兰金量表 置信区间 荟萃分析 优势比 内科学 脑出血 随机对照试验 子群分析 纤溶剂 临床终点 入射(几何) 组织纤溶酶原激活剂 外科 缺血性中风 缺血 蛛网膜下腔出血 物理 光学
作者
Huihui Liu,Huaguang Zheng,Yongjun Cao,Yuesong Pan,David Wang,Runhua Zhang,Shoujiang You,Xinmiao Zhang,Shuya Li,Xu Tong,Chun‐Feng Liu,Yilong Wang
出处
期刊:Journal of stroke and cerebrovascular diseases [Elsevier BV]
卷期号:27 (4): 988-997 被引量:12
标识
DOI:10.1016/j.jstrokecerebrovasdis.2017.11.005
摘要

Background We performed a meta-analysis to compare the efficacy and safety between low- and standard-dose intravenous (IV) tissue-type plasminogen activator (tPA) for acute ischemic stroke (AIS) patients within 4.5 hours of symptom onset. Methods We searched PubMed and EMBASE for relevant studies from inception to June1, 2017. Cohort or randomized controlled studies for AIS within 4.5 hours of symptom onset with comparison between low-dose and standard-dose tPA were included. The primary efficacy end point was favorable functional outcome (modified Rankin scale scores [mRS] of 0-1) at 90 days. The primary safety end point was the incidence rate of symptomatic intracerebral hemorrhage (sICH). The secondary end points were independent functional outcome (mRS scores of 0-2) and mortality. Results A total of 11 studies were pooled in this meta-analysis. The low-dose strategy appeared to be as effective as standard-dose tPA (43.4% versus 45.4%; odds ratio [OR] = 0.93, 95% confidence interval [CI]: 0.78-1.10; P = .38) in primary efficacy outcome. The secondary efficacy outcome produced similar results (57.3% versus 57.0%; OR = 0.95, 95% CI: 0.86-1.05; P = .33). There was no evidence of statistical difference for sICH (4.2% versus 4.9%; OR = 1.02 [0.66-1.55]; P = .94) and mortality (9.0% versus 10.6%; OR = 0.99 [0.74-1.31]; P = .92) at 90 days between low- and standard-dose therapy. In a subgroup analysis by ethnicity, there was no significant difference between patients of Asian and non-Asian descent for any of the end points. Conclusions This study showed that AIS patients receiving low-dose IV-tPA had comparably efficacy and safety to those receiving standard-dose IV-tPA. However, the effect is especially pronounced within the Asian population, which limits the generalizability of these results. We performed a meta-analysis to compare the efficacy and safety between low- and standard-dose intravenous (IV) tissue-type plasminogen activator (tPA) for acute ischemic stroke (AIS) patients within 4.5 hours of symptom onset. We searched PubMed and EMBASE for relevant studies from inception to June1, 2017. Cohort or randomized controlled studies for AIS within 4.5 hours of symptom onset with comparison between low-dose and standard-dose tPA were included. The primary efficacy end point was favorable functional outcome (modified Rankin scale scores [mRS] of 0-1) at 90 days. The primary safety end point was the incidence rate of symptomatic intracerebral hemorrhage (sICH). The secondary end points were independent functional outcome (mRS scores of 0-2) and mortality. A total of 11 studies were pooled in this meta-analysis. The low-dose strategy appeared to be as effective as standard-dose tPA (43.4% versus 45.4%; odds ratio [OR] = 0.93, 95% confidence interval [CI]: 0.78-1.10; P = .38) in primary efficacy outcome. The secondary efficacy outcome produced similar results (57.3% versus 57.0%; OR = 0.95, 95% CI: 0.86-1.05; P = .33). There was no evidence of statistical difference for sICH (4.2% versus 4.9%; OR = 1.02 [0.66-1.55]; P = .94) and mortality (9.0% versus 10.6%; OR = 0.99 [0.74-1.31]; P = .92) at 90 days between low- and standard-dose therapy. In a subgroup analysis by ethnicity, there was no significant difference between patients of Asian and non-Asian descent for any of the end points. This study showed that AIS patients receiving low-dose IV-tPA had comparably efficacy and safety to those receiving standard-dose IV-tPA. However, the effect is especially pronounced within the Asian population, which limits the generalizability of these results.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
zhegewa发布了新的文献求助10
1秒前
3秒前
3秒前
轩轩完成签到,获得积分10
4秒前
夏侯绮山发布了新的文献求助10
4秒前
务实涔发布了新的文献求助10
4秒前
好好学习完成签到,获得积分10
5秒前
独特冰安发布了新的文献求助10
5秒前
handan发布了新的文献求助10
6秒前
whysoserious完成签到,获得积分10
6秒前
nihao完成签到,获得积分10
7秒前
程雯慧完成签到,获得积分10
7秒前
7秒前
沉尘发布了新的文献求助10
8秒前
行为艺术家发布了新的文献求助200
8秒前
花生什么树完成签到,获得积分10
9秒前
酷炫依凝完成签到,获得积分10
10秒前
11秒前
XY发布了新的文献求助10
11秒前
12秒前
CodeCraft应助我爱学习采纳,获得10
12秒前
斯文败类应助内丹翠采纳,获得10
13秒前
14秒前
量子星尘发布了新的文献求助10
14秒前
汏流萤完成签到,获得积分10
14秒前
英俊的铭应助哼哼唧唧采纳,获得10
14秒前
猪猪hero应助wjx采纳,获得10
14秒前
丰富的绮波完成签到 ,获得积分10
14秒前
王赞应助wjx采纳,获得10
14秒前
15秒前
16秒前
Shelton发布了新的文献求助10
17秒前
科研通AI2S应助石慧敏采纳,获得10
17秒前
小蘑菇应助li采纳,获得10
18秒前
19秒前
洗刷刷发布了新的文献求助10
20秒前
Orange应助夏侯绮山采纳,获得10
20秒前
独特冰安发布了新的文献求助10
21秒前
21秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975375
求助须知:如何正确求助?哪些是违规求助? 3519718
关于积分的说明 11199471
捐赠科研通 3256067
什么是DOI,文献DOI怎么找? 1798075
邀请新用户注册赠送积分活动 877386
科研通“疑难数据库(出版商)”最低求助积分说明 806305